Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288531 | 1.00 | CRBN (0.54) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL634048 | 0.93 | CRBN (0.62) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20263311 | 0.85 | CRBN (0.49) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20263394 | 0.85 | CRBN (0.49) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20263313 | 0.85 | CRBN (0.49) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20263392 | 0.85 | CRBN (0.49) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20288555 | 0.85 | CRBN (0.48) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL20288759 | 0.85 | CRBN (0.48) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL632573 | 0.84 | CRBN (0.40) | CRBNIKZF3TNFDDB1BRD4 | |
| SCHEMBL633819 | 0.84 | CRBN (0.40) | CRBNIKZF3TNFDDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885TNF 38/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885TNF 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.